Loading
DL
DA32 Life Science Tech Acquisition Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), was filed 03 Aug 2021.
DA32 Life Science Tech Acquisition Corp.: what insiders have been doing
DA32 Life Science Tech Acquisition Corp. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at DA32 Life Science Tech Acquisition Corp. has published a filing in the past twelve months. The most recent one dates from 10 August 2023.
Over the whole record (from 2021), the tally stands at 3 purchases and no sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€26M
3 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net incomeUS$515.9k
Last declaration on 10 August 2023
Declarations12 total
1,600,000 sharesClass A Common StockSEC:0001062993-23-016234:0
1,600,000 sharesClass A Common StockSEC:0001062993-23-016233:0
1,600,000 sharesClass A Common StockSEC:0001193805-23-001041:0
650,000 shares@ US$10.0044.8% of flowClass A Common StockSEC:0000899243-21-031450:1
650,000 shares@ US$10.0028.9% of flowClass A Common StockSEC:0000899243-21-031411:1
650,000 shares@ US$10.00100.0% of flowClass A Common StockSEC:0000899243-21-031417:1
650,000 shares@ US$10.00100.0% of flowClass A Common StockSEC:0000899243-21-031427:1
▲
Same trade as the filing by Deerfield Management Company, L.P. (Series C), counted once
16M USD37SEC
1,600,000 shares@ US$10.00100.0% of flowClass A Common StockSEC:0000899243-21-031427:0
Canonical exit: 28 Oct 2021 (T+90)
1,600,000 shares@ US$10.00100.0% of flowClass A Common StockSEC:0000899243-21-031411:0
Canonical exit: 28 Oct 2021 (T+90)
650,000 shares@ US$10.00100.0% of flowClass A Common StockSEC:0000899243-21-031406:0
Canonical exit: 28 Oct 2021 (T+90)
800,000 shares@ US$10.00100.0% of flowClass A Common StockSEC:0000899243-21-031450:0
Canonical exit: 28 Oct 2021 (T+90)
▲
Same trade as the filing by Deerfield Management Company, L.P. (Series C), counted once
16M USD28SEC
1,600,000 shares@ US$10.00100.0% of flowClass A Common StockSEC:0000899243-21-031417:0
Canonical exit: 28 Oct 2021 (T+90)
12 of 12 declarations
About DA32 Life Science Tech Acquisition Corp.
DA32 Life Science Tech Acquisition Corp. (ticker: DALS) is a U.S.-listed company trading on the NASDAQ in the United States. It is a special purpose acquisition company, or SPAC, meaning a publicly listed shell vehicle created to complete a merger, stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with a private operating company. According to its SEC filings, DA32 Life Science Tech Acquisition Corp. was incorporated in Delaware on April 16, 2021 and was formed specifically to pursue opportunities in the life sciences technology ecosystem. Its filing history indicates a New York business address at 345 Park Avenue South, 12th Floor, New York, NY 10010, underscoring its U.S.-based financial and transaction-oriented profile.
The company’s core strategy is to identify and combine with a target active in life sciences technology, a broad theme that typically includes research tools, laboratory technologies, diagnostics, digital health, and data-enabled biological platforms. Importantly, DA32 is not an operating company with its own commercial product portfolio. Instead, its value proposition lies in sponsor quality, sector expertise, and the ability to source and complete an attractive business combination. In its original IPO materials, the company highlighted a targeted focus on four major life sciences verticals: life science tools, diagnostics, digital health, and data-driven platforms serving biology and healthcare research.
Read moreShow less
From a competitive standpoint, DALS should be viewed within the crowded SPAC universe, where differentiation comes from the reputation of the sponsors, access to proprietary deal flow, and execution capability. The company was launched by a life sciences-focused collaboration involving Deerfield, ARCH, and Section 32, all of which brought investment and operating experience in healthcare and innovation-driven businesses. That sponsor background was designed to give DALS credibility in evaluating science-heavy companies that may require sophisticated structuring and domain-specific diligence.
Geographically, DALS is a United States entity with a Delaware incorporation and a New York address, and its listing venue is the NASDAQ. For investors in France, Belgium, and Switzerland, the key point is that this is not a traditional commercial healthcare business but a merger vehicle whose risk/reward profile depends on capital deployment, transaction timing, and the quality of the eventual target. As with many healthcare SPACs, the investment case is highly event-driven: if a deal is announced, the market may re-rate the shares based on the implied valuation, target fundamentals, and redemption dynamics; absent a transaction, the company remains primarily a cash-rich acquisition platform rather than an operating issuer.
Recent SEC filings and insider transaction disclosures appear to be the most relevant near-term news flow available for DALS, rather than product launches or operating milestones. That pattern is consistent with a SPAC still focused on capital structure, governance, and business combination activity rather than revenue generation. In short, DALS is best understood as a U.S. NASDAQ-listed life sciences acquisition vehicle with a Delaware legal base, New York presence, and a mandate to create value through a strategic combination in the healthcare innovation landscape.
